DNTH Stock — Dianthus Therapeutics Inc.: Cash, EV, Pipeline

Share price

$96.81

Market cap

$5,415.0M

Cash

$886.8M

Enterprise value

$4,528.2M

Balance sheet

Cash	$886.8M
Debt	$0.0M
Net cash	$886.8M
Enterprise value	$4,528.2M
Basic shares	54.8M shares
Fully diluted shares	66.4M shares
Fully diluted market cap	$6,423.7M
Cash per share	$16.18

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading DNTH daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	Claseprubart	Phase 2	Multifocal Motor Neuropathy	—
Jan 12 - Feb 23	Claseprubart	Phase 3	Myasthenia Gravis, Generalized	2H 2028
Feb 11 - Mar 25	Claseprubart	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Claseprubart

Stage not disclosed · Active Modality: monoclonal antibody

Target C1s

Indications

Myasthenia Gravis, Generalized (Phase 3)
Chronic Inflammatory Demyelinating Polyneuropathy (Phase 3)
Multifocal Motor Neuropathy (Phase 3)

Status note Anti-C1s monoclonal antibody. Primary 10-Q excerpts name claseprubart as a product candidate; stage, indications, and partnerships not stated in the primary excerpts.

DNTH212

Stage not disclosed · Active Modality: fusion protein

Target BDCA2 + BAFF/APRIL

Status note Fusion protein targeting BDCA2 and BAFF/APRIL (target/modality per 10-K fallback). Named as a product candidate in the primary 10-Q; stage and indications not stated in the primary excerpts.

DNTH312

Discovery · Active

Target C1s + BAFF/APRIL

Status note Discovery-stage program named in the primary 10-Q; modality and target not stated.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Claseprubart
Lead indication	Myasthenia Gravis, Generalized
Lead phase	Phase 3
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07647510	Phase 3	Recruiting	Sponsor	DNTH	—	Myasthenia Gravis, Generalized	2H 2028
NCT06858579	Phase 3	Recruiting	Sponsor	DNTH	—	Chronic Inflammatory Demyelinating Polyneuropathy	—
NCT06537999	Phase 2	Active, not recruiting	Sponsor	DNTH	—	Multifocal Motor Neuropathy	—
NCT06282159	Phase 2	Active, not recruiting	Sponsor	DNTH	—	Myasthenia Gravis, Generalized	—
NCT05800509	Not disclosed	Recruiting	Collaborator	National Taiwan University Hospital	—	Gestational Diabetes Mellitus; Postpartum Depression; Perinatal Depression	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Dianthus Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	852,164	no change	0.42%	2026-08-14
Logos Global Management	800,000	+400,000	3.36%	2026-08-14
Braidwell LP	594,562	-304,802	2.14%	2026-08-14
RTW Investments	248,063	no change	0.21%	2026-08-14
OrbiMed Advisors	115,000	+115,000	0.21%	2026-08-14
ADAR1 Capital Management	0	-55,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

DNTH — Dianthus Therapeutics Inc.